Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Main trialPhase 1/2
- “The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 2. To determine the maximum tolerated dose (MTD) or phase 2 recommended dose of TT-10, TT-4 Diacid, and combination therapy (TT-10 + TT-4 Diacid). 3. To evaluate safety of combination therapy (TT-10 + TT-4 Diacid).”In the company’s words, NCT04969315 on ClinicalTrials.gov
Other drugs for Renal Cell Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- BelzutifanMerck & Co. · Phase 3
- AbexinostatXynomic Pharmaceuticals, Inc. · Phase 3
- DurvalumabAstraZeneca · Phase 3
- IpilimumabBristol Myers Squibb · Phase 3
- NivolumabBristol Myers Squibb · Phase 3
Coming up1
- 1 Dec 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Dec 2028 | TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026